tbuckley/cabot-search huggingface dataset:
Abstract 3264: Genome-wide shRNA screen identifies ITIH5 gene as a metastasis suppressor of pancreatic ductal adenocarcinoma (PDAC)
Authors: Ken Sasaki, Hiroshi Kurahara, S Natsugoe, Tomoo Iwakuma, Danny R. Welch
Journal: Cancer Research (2015)

Abstract Background: PDAC is a leading cause of cancer-related death worldwide, and most patients have incurable disease at diagnosis. Life expectancy is only 3-6 months post-diagnosis, ostensibly due to early dissemination to liver and other vital organs. Results: By transfecting a shRNA library into non-metastatic PDAC line S2-028 followed by experimental metastasis assay, ITIH5 was identified. Metastatic PDAC cell lines (e.g., S2-007, MIAPaCa-2, Panc-1) had significantly lower ITIH5 protein expression compared to immortalized pancreatic ductal epithelial cells and non-/poorly-metastatic PDAC cell lines (e.g., S2-028 and BxPC3). By manipulating expression in different PDAC cell lines (over-expression in S2-007 and MIAPaCa-2, knockdown in non-metastatic S2-028 with two different shRNA) functional and selective regulation of metastasis was observed. Orthotopic tumor growth of PDAC cells was not blocked. Thus ITIH5 qualifies as a metastasis suppressor. Overexpression of ITIH5 significantly inhibited invasion and migration, while down-regulation increased these cellular properties. Immunohistochemistry of a human PDAC tissue microarray (n = 81) revealed that negative expression of ITIH5 showed significantly higher incidence of liver metastasis (P = 0.0482) corresponding with worse prognosis after surgery (P = 0.0299). Conclusions: ITIH5 is a potent metastasis suppressor with suggestive prognostic value in PDAC. Future studies will continue to characterize biochemical properties of ITIH5, identify interaction partners, and investigate the molecular mechanism(s) of action. Support: National Foundation for Cancer Research, Steiner Family Fund and CA168524. Citation Format: Ken Sasaki, Hiroshi Kurahara, S Natsugoe, Tomoo Iwakuma, Danny R. Welch. Genome-wide shRNA screen identifies ITIH5 gene as a metastasis suppressor of pancreatic ductal adenocarcinoma (PDAC). [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3264. doi:10.1158/1538-7445.AM2015-3264
Abstract 4661: Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice
Authors: Takayasu Ideta
Journal: Cancer Research (2015)

Abstract In the present study, the effects of BCAA supplementation on the spontaneous development of hepatic premalignant lesions, foci of cellular alteration, in db/db obese mice were examined. Male db/db mice were given a basal diet containing 3.0% of either BCAA or casein, a nitrogen-content-matched control of BCAA, for 36 weeks. On killing the mice, supplementation with BCAA significantly inhibited the development of foci of cellular alteration when compared with casein supplementation by inhibiting cell proliferation, but inducing apoptosis. BCAA supplementation increased the expression levels of peroxisome proliferator-activated receptor-γ(PPARγ), p21(CIP1) and p27(KIP1) messenger RNA and decreased the levels of c-fos and cyclin D1 mRNA in the liver. BCAA supplementation also reduced both the amount of hepatic triglyceride accumulation and the expression of interleukin (IL)-6, IL-1β, IL-18 and tumor necrosis factor-α mRNA in the liver. Increased macrophage infiltration was inhibited and the expression of IL-6, TNF-α, and monocyte chemoattractant protein-1 mRNA in the white adipose tissue were each decreased by BCAA supplementation. BCAA supplementation also reduced adipocyte size while increasing the expression of PPARα, PPARγand adiponectin mRNA in the white adipose tissue compared with casein supplementation. These findings indicate that BCAA supplementation inhibits the early phase of obesity-related liver tumorigenesis by attenuating chronic inflammation in both the liver and white adipose tissue. BCAA supplementation may be useful in the chemoprevention of liver tumorigenesis in obese individuals. Citation Format: Takayasu Ideta. Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4661. doi:10.1158/1538-7445.AM2015-4661
Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma
Authors: Jonas Paludo, Nishanth Vallumsetla, Shaji Kumar, Rhett Ketterling, Morie A Gertz, Angela Dispenzieri, Martha Q Lacy, Francis K Buadi, David Dingli, Utkarsh Painuly, Nelson Leung, Robert Kyle, S. Vincent Rajkumar, Prashant Kapoor
Journal: Blood (2014)
The Future of the <i>DSM</i>
Authors: Michael B. First, Kenneth S. Kendler, Ellen Leibenluft
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
SP0037 What To Do When A Fracture Occurs after 3 Years Treatment with An Oral Bisphosphonate?
Authors: B. Langdahl
Journal: Annals of the Rheumatic Diseases (2016)

Osteoporosis is characterised by reduced bone mass, deteriorated bone architecture and increased risk of fractures. A fracture in a patient with osteoporosis is therefore not uncommon, not even in treated patients as none of the available treatments can prevent fractures completely. Despite this knowledge a fracture is a disturbing event for the patient and should prompt the treating physician to consider the situation. First of all, compliance with the treatment including supplementation with calcium and vitamin D should be checked. Secondly, competing diseases and treatments and other risk factors may have emerged since the patient was diagnosed and started on treatment, and these conditions may attenuate the anti-fracture efficacy of the treatment (thyrotoxicosis, prednisolone, aromatase inhibitors etc). If compliance is good and no new risk factors have emerged, treatment failure should be considered. Treatment failure can be assessed by new fractures, changes in BMD or bone turnover markers. Treatment failure is suggested if treatment has been ongoing for more than 12 months with good compliance and 2 or more new fractures occur or 1 new fracture in combination with declining BMD or non-suppressed bone turnover markers or BMD declines in combination with non-suppressed bone turnover markers. If treatment failure is demonstrated then the treatment should be reconsidered. The absorption of oral bisphosphonates is 1–2% under optimal conditions, so the first alternative would be intravenous zoledronic acid or alternatively denosumab. Both are strong antiresorptives which have been proven to be able to increase BMD and suppress bone turnover in patients previously treated with oral bisphosphonates. If the incident fracture is a vertebral fracture, it could also be considered to change to teriparatide, a bone forming treatment with very prominent effects on spine BMD and vertebral fractures. <h3>Disclosure of Interest</h3> B. Langdahl Grant/research support from: Novo Nordisk, Eli Lilly, Orkla Health, Consultant for: Merck, Eli Lilly, Amgen, UCB, Speakers bureau: Merck, Amgen, Eli Lilly
Identification of Sensitizing Targets to the Hypomethylating Agent 5-Azacytidine in Acute Myeloid Leukemia Cells Using RNAi-Based Functional Genomics Screening
Authors: Raoul Tibes, Ashish Choudhary, Amanda Henrichs, Sadia Guled, Irma Monzon, Lourdes Peralta, Spyro Mousses, David Azorsa
Journal: Blood (2008)
Identification of CHMP5 as an anti-apoptotic gene by shRNA-based RNAi-screening
Authors: Maria Shahmoradgoli, Otto Mannherz, Stefanie Heck, Martina Seiffert, Peter Lichter, Armin Pscherer
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

2702 

RNA interference (RNAi) is a natural mechanism by which small interfering RNA (siRNA)or short hairpin RNA (shRNA) can mediate degradation of a target RNA molecule in a sequence-specific manner. Here we describe a loss-of-function screen for 288 functionally uncharacterized human genes sensitive for inhibiting apoptosis in HEK293 cells. Using a shRNA-based RNAi library subset, we identified a new anti-apoptotic function for CHMP5 (Charged Multivesicular Body Protein5), which we could validate by caspase inhibitor- and gain of function-assays. In addition, based on NF-kB-luciferase reporter assays we elucidate inhibitory effects of CHMP5 for the NF-kB (Neuclear Factor-kB) pathway. Investigating the effect of CHMP5 gene activity modulation on death receptor TNFR1 (Tumor Necrosis Factor Receptor1) protein turnover, we observed decreased cellular surface expression of TNFR1 in CHMP5 over-expressing cells. Taken together our data reveal new anti-apoptotic function for CHMP5 by modulating the TNFR1 death receptor turnover and thereby affecting the NFkB signalling pathway.
Mitigating Financial Toxicity Among US Patients With Cancer
Authors: Jonas A. de Souza, Rena M. Conti
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
O076 : Cardiac volume overload and pulmonary hypertension after long-term follow-up in TIPS patients
Authors: T.A. Hippchen, A. Wannhoff, K. Friedrich, C. Rupp, K.-H. Weiss, P. Schemmer, B. Radeleff, W. Stremmel, D.N. Gotthardt
Journal: Journal of Hepatology (2015)
SAT0583 A Systematic Review of Systemic Sclerosis Instruments for The Eular Outcome Measures Library: An Evolutionary Database of Validated Patient-Reported Instruments: Table 1
Authors: F. Ingegnoli, L. Carmona, I. Castrejon
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Over time, a patient-centered evaluation of health status has become more important for systemic sclerosis (SSc), both in research and clinical setting. Patient-reported outcomes (PROs) are being increasingly used to measure various domains of disease status relevant to patients and physicians. The EULAR Outcome Measures Library (OML) is a freely available website with structured access to a growing database of validated PROs [1], but currently there are no PROs available on SSc at the EULAR OML. <h3>Objectives</h3> To provide a comprehensive review of validated SSc-specific PROs and to critically appraise their validity. <h3>Methods</h3> A sensitive search was developed in Medline and Embase (08/2015) to identify all validation studies, cohort studies, reviews or metaanalyses in which the objective were the development or validation of PROs evaluating organ involvement, disease activity or damage in SSc. A reviewer screened title and abstracts, selected the studies, and collected data concerning validation using ad hoc forms based on the COSMIN checklist. <h3>Results</h3> From 13,140 articles captured, 74 met the predefined criteria. After excluding an instrument for the unavailability of an English version, the selected studies provided information on 6 SSc-specific PROs: the Scleroderma Assessment Questionnaire (SAQ), the scleroderma functional score (FS), the Raynaud9s condition score (RCS), the Mouth Handicap in SSc (MHISS), the University of California Los Angeles-Scleroderma Clinical Trial Consortium Gastro-Intestinal tract (UCLA-SCTC-GIT 2.0), and the Skin Self-Assessment. The table summarizes the instruments and their measurement properties: <h3>Conclusions</h3> Six SSc-specific PROs have a minimum validation and will be included in the EULAR OML. In general, the level of validation attained could be improved. Further development in the area of disease-specific PROs in SSc is warranted. <h3>References</h3> Castrejόn I, Gossec L, Carmona L. Ann Rheum Dis. 2015;74(2):475–6 <h3>Disclosure of Interest</h3> None declared
Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.
Authors: Domenico Russo, Gianantonio Rosti, Giovanni Martinelli, Michele Malagola, Salvatore Mirto, Diamante Turri, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Francesco Di Raimondo, Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Vincenzo Liso, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Giovanni Quarta, Mariella Girasoli, Alberto Bosi, Valeria Santini, Giuseppe Fioritoni, Roberto Di Lorenzo, Chiara Colombi, Miriam Fogli, Marilina Amabile, Nicoletta Testoni, Antonio De Vivo, Michele Baccarani
Journal: Blood (2009)
High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention
Authors: Gjin Ndrepepa, Roisin Colleran, Siegmund Braun, Salvatore Cassese, Julia Hieber, Massimiliano Fusaro, Sebastian Kufner, Ilka Ott, Robert A. Byrne, Oliver Husser, Christian Hengstenberg, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati
Journal: Journal of the American College of Cardiology (2016)
AB0071 Alpha-Enolase Expression on The Cell Surface of Osteoclast Precursors Plays A Positive Role in Osteoclastogenesis of Monocyte/macrophage in Rheumatoid Arthritis
Authors: J.H. Shin, J.E. Song, J.S. Park, S.H. Shon, E.Y. Lee, E.B. Lee, Y.W. Song
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The local bone loss around the inflamed joints is found from the early stage of rheumatoid arthritis. We previously reported that cell-surface expression of alpha-enolase (ENO1), multifunctional glycolytic protein, is increased in monocytes and macrophages isolated from RA patients and related to production of proinflammatory cytokines (1). <h3>Objectives</h3> This study was performed to examine the role of surface ENO1 on osteoclastogenesis in rheumatoid arthritis. <h3>Methods</h3> Monocytes isolated from RA patients and healthy control were used to examine the surface level of ENO1 by flow cytometry and confocal microscopy. U937, human monocytic cell line, was treated with ENO1-targeting siRNA (siENO1) to down-regulate ENO1 expression, then osteoclast differentiation were induced by RANKL and the level of ENO1 and NFATc1 was measured. Also, monocytes from RA patients were differentiated into macrophages and transfected with siENO1 to assess the effect on osteoclast differentiation. <h3>Results</h3> We found the surface expression level of ENO1 was higher in monocytes isolated from RA patients than healthy control and gradually decreased during osteoclastogenesis in both cells, while the total level of ENO1 remained unchanged. ENO1-specific siRNA significantly decreased the surface ENO1 level in U937, but did not affect the viability and proliferation of the cells. When osteoclast formation was induced by RANKL, osteoclast-specific transcription factor, nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) expression was markedly inhibited in ENO1 down-regulated cells compared to control cells. We also examined the effect of down regulation of ENO1 in osteoclast precursor cells isolated from RA patients (N=10). The surface ENO1 level was significantly decreased and RANKL-induced osteoclast differentiation was markedly inhibited in ENO1 down-regulated cells compared to control cells. <h3>Conclusions</h3> These results suggest that increased expression level of ENO1 on the surface of monocytes/macrophages have positive effect on osteoclast formation in RA. <h3>References</h3> S. Bae, H. Kim, N. Lee, C. Won, H-R. Kim, Y. Hwang, Y W. Song, J S. Kang, and W J. Lee. A-Enolase expressed on the surfaces of monocytes and macrophages induces robust synovial inflammation in rheumatoid arthritis. The Journal of Immunology. (2012) 189: 365–372. <h3>Disclosure of Interest</h3> None declared
Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease
Authors: Douglas C. Dean, Samuel A. Hurley, Steven R. Kecskemeti, J. Patrick O’Grady, Cristybelle Canda, Nancy J. Davenport-Sis, Cynthia M. Carlsson, Henrik Zetterberg, Kaj Blennow, Sanjay Asthana, Mark A. Sager, Sterling C. Johnson, Andrew L. Alexander, Barbara B. Bendlin
Journal: JAMA Neurology (2016)

The accumulation of aggregated β-amyloid and tau proteins into plaques and tangles is a central feature of Alzheimer disease (AD). While plaque and tangle accumulation likely contributes to neuron and synapse loss, disease-related changes to oligodendrocytes and myelin are also suspected of playing a role in development of AD dementia. Still, to our knowledge, little is known about AD-related myelin changes, and even when present, they are often regarded as secondary to concomitant arteriosclerosis or related to aging.To assess associations between hallmark AD pathology and novel quantitative neuroimaging markers while being sensitive to white matter myelin content.Magnetic resonance imaging was performed at an academic research neuroimaging center on a cohort of 71 cognitively asymptomatic adults enriched for AD risk. Lumbar punctures were performed and assayed for cerebrospinal fluid (CSF) biomarkers of AD pathology, including β-amyloid 42, total tau protein, phosphorylated tau 181, and soluble amyloid precursor protein. We measured whole-brain longitudinal and transverse relaxation rates as well as the myelin water fraction from each of these individuals.Automated brain mapping algorithms and statistical models were used to evaluate the relationships between age, CSF biomarkers of AD pathology, and quantitative magnetic resonance imaging relaxometry measures, including the longitudinal and transverse relaxation rates and the myelin water fraction.The mean (SD) age for the 19 male participants and 52 female participants in the study was 61.6 (6.4) years. Widespread age-related changes to myelin were observed across the brain, particularly in late myelinating brain regions such as frontal white matter and the genu of the corpus callosum. Quantitative relaxometry measures were negatively associated with levels of CSF biomarkers across brain white matter and in areas preferentially affected in AD. Furthermore, significant age-by-biomarker interactions were observed between myelin water fraction and phosphorylated tau 181/β-amyloid 42, suggesting that phosphorylated tau 181/β-amyloid 42 levels modulate age-related changes in myelin water fraction.These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process. We expect that clarifying the nature of myelin damage in preclinical AD may be informative on the disease's course and lead to new markers of efficacy for prevention and treatment trials.
Quantification of MDM2 Gene Expression Level by RQ-PCR Is Predictive of the First Complete Remission in Adulte Acute Myeloid Leukaemia.
Authors: Nathalie Gachard, Pascal Turlure, Franck Trimoreau, Stephane Moreau, Magali Donnard, Marie-Pierre Chaury, Rachel Pradeau, Dominique Bordessoule, Jean Feuillard
Journal: Blood (2004)
Trisomy 13, AML1 Mutations and M0 Subtype Are Remarkably Intricate Events in Acute Myeloid Leukemia (AML).
Authors: Olivier Nibourel, Christophe Roumier, Nathalie Philippe, Sabine Quief, Celine Villenet, Jean-Luc Laï, Nicole Dastugue, Isabelle Tigaud, John de Vos, Jean Soulier, Antonio Alberdi, Daniela Geromin, Eric Delabesse, Jean-Pierre Kerckaert, Claude Preudhomme
Journal: Blood (2007)
Efficacy and Safety of Deferasirox in Patients with Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation: The CICL670ADE02 Trial
Authors: Haifa Kathrin Al-Ali, Nadja Jaekel, Kai Lieder, Stefan Albrecht, Oliver Leismann, Karolin Hubert, Gesine Bug, Nicolaus Kroeger, Uwe Platzbecker, Michael Stadler, Katherina de Haas, Dietger Niederwieser
Journal: Blood (2012)
Current Activities of AsiaCORD: Fast Searching System of the Qualified Cord Blod Units for Asian Patients.
Authors: Tsuneo A. Takahashi, Kai Hsin Lin, Hoon Han, Tran van Binh, Nguyen Tan Binh, Zhongchao Han, Kai Yan Liu, Surapol Issaragrisil, Hideki Kodo, Shigetaka Asano, Dao Pei Lu
Journal: Blood (2004)
Transplant Outcome of Unrelated Hematopoietic Stem Cell Transplantation (HSCT) after Myelo-Ablative or Reduced Intensity Conditioning (RIC) for Chronic Lymphocytic Leukemia(CLL). A Study of EBMT Registry.
Authors: Mauricette Michallet, Thomas Prebet, Quoc-Hung Le, Anne-Sophie Michallet, Anja Van Biezen, Ronald Brand, Peter Dreger, Dietger W. Niederwieser
Journal: Blood (2005)
Decision Criteria for the Futility of Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML).
Authors: Hervé Dombret, Jean-Valère Malfuson, Anne Etienne, Pascal Turlure, Thierry de Revel, Xavier Thomas, Nathalie Contentin, Christine Terré, Mauricette Michallet, Sylvie Castaigne, Dominique Bordessoule, Norbert Vey, Claude Gardin
Journal: Blood (2007)
B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
Authors: Beiying Dai, Michael Grau, Mélanie Juilland, Pavel Klener, Elisabeth Höring, Jan Molinsky, Gisela Schimmack, Sietse M. Aukema, Eva Hoster, Niklas Vogt, Annette M. Staiger, Tabea Erdmann, Wendan Xu, Kristian Erdmann, Nicole Dzyuba, Hannelore Madle, Wolfgang E. Berdel, Marek Trneny, Martin Dreyling, Korinna Jöhrens, Peter Lenz, Andreas Rosenwald, Reiner Siebert, Alexandar Tzankov, Wolfram Klapper, Ioannis Anagnostopoulos, Daniel Krappmann, German Ott, Margot Thome, Georg Lenz
Journal: Blood (2016)